John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.
[More]
Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop.
[More]
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
[More]
Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.
[More]
Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found.
[More]
People diagnosed with cancer are more than two-and-a-half times more likely to declare bankruptcy than those without cancer, according to a new study from Fred Hutchinson Cancer Research Center. Researchers also found that younger cancer patients had two- to five-fold higher bankruptcy rates compared to older patients, and that overall bankruptcy filings increased as time passed following diagnosis.
[More]
Depressed cancer survivors are twice as likely to die prematurely than those who do not suffer from depression, irrespective of the cancer site. That's according to a new study, by Floortje Mols and colleagues, from Tilburg University in The Netherlands.
[More]
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
[More]
The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
[More]
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.
[More]
The annual Century for the Cure bike ride that has raised more than $1 million since 2005 for research at The Cancer Institute of New Jersey is now making it possible for new scientific exploration in the area of hematologic malignancies.
[More]
Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center have found a combination of drugs to potentially treat chronic lymphocytic leukemia more effectively.
[More]
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).
[More]
Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers at the Knight Cancer Institute at Oregon Health & Science University.
[More]
John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.
[More]
The understanding of how a powerful protein called p53 protects against cancer development has been upended by a discovery by Walter and Eliza Hall Institute researchers. More than half of human cancers carry defects in the gene for p53, and almost all other cancers, with a normal p53 gene, carry other defects that somehow impair the function of the p53 protein. Inherited mutations in the p53 gene put people at a very high risk of developing a range of cancers.
[More]
Many medical issues affect nerves, from injuries in car accidents and side effects of chemotherapy to glaucoma and multiple sclerosis. The common theme in these scenarios is destruction of nerve axons, the long wires that transmit signals to other parts of the body, allowing movement, sight and sense of touch, among other vital functions.
[More]
Although the government releases a list of what hospitals across the country charge for common procedures in an effort to make health costs more transparent, few patients or their insurers pay that.
[More]
Today's headlines include reports about the politics surrounding the health law, both in terms of the latest GOP push for repeal and the Obama administration's implementation efforts.
[More]
Loyola University Medical Center has opened a new 20-bed unit for patients undergoing stem cell transplants for cancers such as leukemia, lymphoma and multiple myeloma.
[More]